Curaleaf International

This year has been pivotal for Curaleaf International and the global #cannabis industry. Germany’s bold reforms, expanding into new markets, welcoming talented new colleagues, and strengthening our position as industry leaders. Many challenges remain but we are driving innovation, expanding access and shaping the future of cannabis. Read Juan Martinez, Head of Curaleaf International, reflections on 2024 👇 Curaleaf Four 20 Pharma GmbH Curaleaf Clinic Curaleaf Pharmacy Curaleaf Laboratories

Interesting new research from the team at Curaleaf Clinic focused on sleep and chronic pain with over 1,000 participants. While the study shows promising associations, it doesn’t definitively prove cause-and-effect and more research is still needed to understand the therapeutic potential of medical cannabis.

A BBC News feature delves into the seed-to-patient journey at Curaleaf with journalist Adam Clarkson visiting our Portuguese cultivation site and our state-of-the-art manufacturing facility in Sunderland Curaleaf Laboratories. Nuno Mendonça, General Manager of Iberia for Curaleaf International, emphasises the importance of our rigorous approach to cultivation and production: "The users of the illicit market have no idea what's behind the product they are purchasing. One of the most important aspects of production is to get consistency.” Since medical cannabis was legalised in the UK in 2018, Curaleaf has significantly expanded patient access, providing care to tens of thousands of patients with conditions such as anxiety, depression and chronic pain. Watch the full BBC News report to find out more and hear from Curaleaf Clinic patients https://lnkd.in/ex9z7fGK #BBCNews #CuraleafInternational #Curaleaf #MedicalCannabis

In the latest research published this month from the team at Curaleaf Clinic, outcomes from 302 patients with generalised anxiety disorder were analysed. Cannabis-based medicinal products (CBMPs) were associated with improvements in anxiety, sleep quality and quality of life over 12 months. By analysing patient data from the UK Medical Cannabis Registry (UKMCR), real-world evidence supports the potential impact of CBMPs on a range of treatment-resistant conditions. More research is needed to determine optimal formulations and the long-term effects. Read the full paper: https://shorturl.at/fwkcG

Today marks a milestone for the UK: six years since the law change allowing the prescription of medical cannabis. Some of the positive developments driven by Curaleaf during this time include:    ➡️ Improved patient access to treatment: Launching the first regulated medical cannabis clinic Curaleaf Clinic and capturing essential evidence from over 30,000 patients via the proprietary UK Medical Cannabis Registry, the largest medical cannabis registry in Europe. ➡️ Manufacturing expansion: Establishing a wide range of product formats, including flower, oils, pastilles, and liquid vape cartridges, through the first laboratory in the UK dedicated to manufacturing medical cannabis, Curaleaf Laboratories. ➡️ Research advancements: In partnership with various academic institutions, the research team have accelerated the understanding of the therapeutic potential of medical cannabis with over 50 peer-reviewed studies on this topic. Whilst these achievements are significant, more needs to be done to champion patient access to medical cannabis through awareness, education and reducing financial barriers to this treatment option. #CannabisResearch #MedicalCannabisUK #Curaleaf #6YearsofMedicalCannabis 

Our report in collaboration with MANDRAK Lab, The Hidden Dangers of Illicit Cannabis shows that 73% of those purchasing illicit cannabis online are seeking relief from health conditions like chronic pain and anxiety. These consumers are at risk of exposure to harmful contaminants, despite legal alternatives being available. Dr Oliver Sutcliffe, Senior Lecturer at The Manchester Metropolitan University has said “Our findings serve as a stark reminder of the importance of vigilance and education in protecting public health” Learn more about the public health implications of illicit cannabis: https://shorturl.at/BkT4C #CannabisSafety #HealthRisks #ManchesterMetUni #CuraleafClinic

Curaleaf’s latest report, The Hidden Dangers of Illicit Cannabis, reveals the alarming rise in online illegal cannabis sales, which have grown 50% over the past two years. The unregulated market exposes consumers to potentially serious health risks from mould and lead contamination. Read the full white paper to learn: ➡️ The implications of illicit cannabis for public health and patient safety  ➡️ A range of actions policymakers can take to mitigate the risks  ➡️ Why expanding research into medical cannabis can help to unlock its therapeutic potential Available here thanks to a Curaleaf Clinic and MANDRAKE collaboration: https://shorturl.at/BkT4C #CannabisResearch #MedicalCannabis #CuraleafClinic

Dr Mikael Sodergren x Business of Cannabis Podcast Here is Dr Mikael Sodergren on the Business of Cannabis | Europe Podcast talking to Shahbaaz Kara-Virani about Europe's largest patient registry, “The registry has over 24,000 entries of patient data, which informs us on the optimal dosage for certain demographics and medical form factors” The UK Medical Cannabis Registry collects unprecedented insights into patient outcomes and the real-world impact of medical cannabis treatments. Listen to the full episode to learn: ➡️  Dr Mikael Sodergren’s journey into the industry and his passion behind medical cannabis research  ➡️  Research outcomes of studies conducted on neuropathic pain and investigating the analgesic effect of cannabinoids ➡️  How Curaleaf Clinic is educating patients and the clinic expansion to Sweden via Sapphire Clinics ➡️  The future of medical cannabis in the UK and beyond Listen to the full podcast episode here | Spotify - https://shorturl.at/tpmvy | Apple - https://shorturl.at/5g3UL —- Show your support for Curaleaf’s leading research team Dr Mikael Sodergren and Dr Simon Erridge who have been nominated for a joint Contribution to Science award! | Vote here: https://lnkd.in/e4Ge4YxX | Voting closes in 1 Day

Show your support for lead researchers Dr Mikael Sodergren and Dr Simon Erridge who have been nominated for a joint Contribution to Science award! Their dedication to advancing research in the cannabis industry is making a real impact in the scientific community. We are beyond proud of their contributions. Scroll to see why they deserve your vote ➡️ Voting closes on the 24th October | Vote here: https://lnkd.in/e4Ge4YxX #OneCuraleaf #CannabisAwards #MedicalCannabis #ImperialCollegeLondon

“ENDLICH” is the campaign changing perceptions of cannabis in Germany ⬇️ Since 1st April, cannabis has been partially legalised in Germany, and with the removal of cannabis from the narcotics list, doctors can now prescribe medical cannabis more easily. The “ENDLICH” campaign which launched shortly after the law changed, aims to provide objective information on cannabis with the help of leading figures in Germany. This month, a collaboration between Four 20 Pharma GmbH, Sanity Group and SC Paderborn 07 GmbH & Co. KGaA, successfully launched a special “ENDLICH” jersey to promote awareness about medical cannabis and reduce the stigma associated with its use. Find out more about this initiative: https://lnkd.in/eQtVTi6r #MedicalCannabis #ENDLICH #CannabisAwareness #CanG